Clovis Oncology Inc said on Friday the U.S. Food and Drug Administration has approved its drug Rubraca for the treatment of adult patients with metastatic castration-resistant prostate cancer, whose tumors have a genetic mutation. The approval is for the drug's use as monotherapy in patients whose tumors have a mutation called BRCA, and whose disease had advanced despite chemotherapy and hormone-directed therapy, the company said.